Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Crohn’s disease ( CD ) is a chronic debilitating illness with limited effective treatment options, especially for patients with moderate to severe disease. Treatment options for CD include conventional, largely generic small molecules and more-potent biologics. Despite the clinical and commercial success of the tumor-necrosis factor-alpha ( TNF -α) inhibitors, opportunity remains for agents that can safely and effectively induce and maintain remission in greater numbers of patients with moderate to severe CD . Indeed, the cell adhesion molecule ( CAM ) inhibitor vedolizumab (Takeda’s Entyvio) is an option for adult patients with moderate to severe CD who have failed conventional therapies and/or TNF -α inhibitors. The interleukin ( IL )-12/ IL -23 inhibitor ustekinumab (Janssen’s Stelara), which was recently approved in the United States and received a positive opinion in Europe, is expected to launch in both regions for CD during the 2015-2025 study period. Other promising agents in late-stage development that are geared toward the moderate to severe CD population include Roche’s CAM inhibitor etrolizumab, Galapagos’s JAK inhibitor filgotinib, and the oral SMAD7 antisense oligonucleotide mongersen (Celgene’s GED-0301). This Disease Landscape and Forecast provides a detailed analysis of these late-phase pipeline candidates and an annualized ten-year forecast for the CD therapy market (2015-2025) in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Detailed, updated epidemiological estimates and in-depth coverage of the current treatment landscape are also included.